Contribution of PKB/AKT signaling to thyroid cancer

Frontiers in Bioscience

Volumn 16, Issue 4, 2011, Pages 1461-1487

  Viglietto, Giuseppe ^a,b   Amodio, Nicola ^a   Malanga, Donatella ^a,b   Scrima, Marianna ^b   De Marco, Carmela ^a,b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b Institute for Genetic Research G Salvatore   (Italy)

Author keywords

AKT; Genetic alteration; PI3K; Review; Thyroid cancer

Indexed keywords

MAMMALIA;

MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PTEN PROTEIN, HUMAN; RAS PROTEIN; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; CARCINOMA; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; THYROID FOLLICULAR CARCINOMA; THYROID TUMOR;

APOPTOSIS; CARCINOMA; CARCINOMA, PAPILLARY, FOLLICULAR; CELL PROLIFERATION; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 79955026966     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3799     Document Type: Article

References (255)

1. L Leenhardt, P Grosclaude, L Chérié-Challine; Thyroid Cancer Committee: Increased incidence of thyroid carcinoma in france: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 14, 1056-60 (2004) (Pubitemid 40076130)
2. L Davies, HG Welch: Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295, 2164-7 (2006)
3. RA DeLellis, RV Lloyd, PU Heitz, C Eng (Eds): Pathology and Genetics of Tumours of Endocrine Organs. World Health Organization Classification of Tumours. IARC Press, 137-46 (2004)
4. S Cooper, GM Doherty, BR Haugen, RT Kloos, SL Lee, SJ Mandel, EL Mazzaferri, B McIver, SI Sherman, RM Tuttle; American Thyroid Association Guidelines Taskforce: Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16, 109-42 (2006)
5. A Stojadinovic, R Ghossein, A Hoos, MJ Urist, RH Spiro, JP Shah, MF Brennan, AR Shaha, B Singh: Hürthle cell carcinoma: a critical histopathological appraisal. J Clin Oncol 19, 2616-2625 (2001) (Pubitemid 32441366)
6. J Rosai, M Caracangui, R DeLellis: Tumors of the thyroid gland. In: Atlas of Tumor Pathology, 3rd series, fascicle. Eds: J. Rosai and L. H. Sobin (1992)
7. KB Ain: Management of undifferentiated thyroid cancer. Baillieres Best Pract Res Clin Endocrinol Metab 14, 615-29 (2000) (Pubitemid 32293858)
8. WR Cornett, AK Sharma, TA Day, MS Richardson, RS Hoda, JA van Heerden, J K Fernandes: Anaplastic thyroid carcinoma: an overview. Curr Oncol Rep 9, 152-8 (2007) (Pubitemid 46332389)
9. MN Nikiforova, YE Nikiforov: Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 8, 83-95 (2008)
10. M Xing: Recent advances in molecular biology of thyroid cancer and their clinical implications. Otolaryngol Clin North Am 41, 1135-46 (2008)
11. PP Roger, WC van Staveren, K Coulonval, JE Dumont, C Maenhaut: Signal transduction in the human thyrocyte and its perversion in thyroid tumors. Mol Cell Endocrinol 321, 3-19 (2010)
12. T Pilli, KV Prasad, S Jayarama, F Pacini, BS Prabhakar: Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer. Thyroid 19, 1333-42 (2009)
13. RE Schweppe, JP Klopper, C Korch, U Pugazhenthi, M Benezra, JA Knauf, JA Fagin, LA Marlow, JA Copland, RC Smallridge, BR Haugen: Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93, 4331-41 (2008) (Pubitemid 352789529)
14. WC van Staveren, DW Solís, L Delys, L Duprez, G Andry, B Franc, G Thomas, F Libert, JE Dumont, V Detours, C Maenhaut: Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype. Cancer Res 67, 8113-20 (2007) (Pubitemid 47395146)
15. MD Ringel: "Thyroid cancer" cell line misidentification: a time for proactive change. J Clin Endocrinol Metab 93, 4226-7 (2008) (Pubitemid 352789514)
16. CS Kim, X Zhu: Lessons from mouse models of thyroid cancer. Thyroid 9, 1317-31 (2009)
17. B Vanhaesebroeck, MD Waterfield: Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 253, 239-54 (1999)
18. SR Datta, A Brunet, ME Greenberg: Cellular survival: a play in three Akts. Genes Dev 13, 2905-27 (1999)
19. I Vivanco, CL Sawyers: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2, 489-501 (2002) (Pubitemid 37328931)
20. JR Testa, A Bellacosa: AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U S A 98, 10983-5 (2001) (Pubitemid 32928669)
21. DP Brazil, ZZYang, BA Hemmings: Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 29, 233-42 (2004) (Pubitemid 38591317)
22. J Okano, I Gaslightwala, MJ Birnbaum, AK Rustgi, H Nakagawa: Akt/protein kinase B isoforms aredifferentially regulated by epidermal growth factor stimulation. J Biol Chem 275, 30934-42 (2000)
23. WS Chen, PZ Xu, K Gottlob, ML Chen, K Sokol, T Shiyanova, I Roninson, W Weng, R Suzuki, K Tobe, T Kadowaki, N Hay: Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev 15, 2203-8 (2001) (Pubitemid 32843832)
24. H Cho, JL Thorvaldsen, Q Chu, F Feng, MJ Birnbaum: Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem 276, 38349-52 (2001)
25. H Cho, J Mu, JK Kim, JL Thorvaldsen, Q Chu, EB Crenshaw 3rd, KH Kaestner, MS Bartolomei, GI Shulman, MJ Birnbaum: Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292, 1728-31 (2001) (Pubitemid 32506248)
26. RS Garofalo, SJ Orena, K Rafidi, AJ Torchia, JL Stock, AL Hildebrandt, T Coskran, SC Black, DJ Brees, JR Wicks, JD McNeish, KG Coleman: Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J Clin Invest 112, 197-208 (2003) (Pubitemid 38056356)
27. O Tschopp, ZZ Yang, D Brodbeck, BA Dummler, M Hemmings-Mieszczak, T Watanabe, T Michaelis, J Frahm, BA Hemmings: Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis. Development 132, 2943-54 (2005) (Pubitemid 41086730)
28. XD Peng, PZ Xu, ML Chen, A Hahn-Windgassen, J Skeen, J Jacobs, D Sundararajan, WS Chen, SE Crawford, KG Coleman, N Hay: Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 17, 1352-65 (2003) (Pubitemid 36666005)
29. ZZ Yang, O Tschopp, N Di-Poï, E Bruder, A Baudry, B Dümmler, W Wahli, BA Hemmings: Dosagedependent effects of Akt1/protein kinase Balpha (PKBalpha) and Akt3/PKBgamma on thymus, skin, and cardiovascular and nervous system development in mice. Mol Cell Biol 25, 10407-18 (2005) (Pubitemid 41681964)
30. B Dummler, O Tschopp, D Hynx, ZZ Yang, S Dirnhofer, BA Hemmings: Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are viable but display impaired glucose homeostasis and growth deficiencies. Mol Cell Biol 26, 8042-51 (2006) (Pubitemid 44631003)
31. RM Easton, H Cho, K Roovers, DW Shineman, M Mizrahi, MS Forman, VM Lee, M Szabolcs, R de Jong, T Oltersdorf, L Ludwig, A Efstratiadis, MJ Birnbaum: Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol Cell Biol 25, 1869-78 (2005) (Pubitemid 40280150)
32. HY Irie, RV Pearline, D Grueneberg, M Hsia, P Ravichandran, N Kothari, S Natesan, JS Brugge: Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol 171, 1023-34 (2005) (Pubitemid 41815834)
33. IG Maroulakou, W Oemler, SP Naber, PN Tsichlis: Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res 67, 167-77 (2007) (Pubitemid 46142772)
34. M Yoeli-Lerner, GK Yiu, I Rabinovitz, P Erhardt, S Jauliac, A Toker: Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell 20, 539-50 (2005) (Pubitemid 41668639)
35. E Bousquet, J Mazieres, M Privat, V Rizzati, A Casanova, A Ledoux, E Mery, B Couderc, G Favre, A Pradines: Loss of RhoB Expression Promotes Migration and Invasion of Human Bronchial Cells Via Activation of AKT1. Cancer Res 69, 6092-6099 (2009)
36. EK Kim, SJ Yun, KH Do, MS Kim, D Suh, CD Kim, JH Kim, MJ Birnbaum, SS Bae: Lysophosphatidic acid induces cell migration through the selective activation of AKT1. Exp Mol Med 40, 445-452 (2008)
37. V Vasko, M Saji, E Hardy, M Kruhlak, A Larin, V Savchenko, M Miyakawa, O Isozaki, H Murakami, T Tsushima, KD Burman, C De Micco, MD Ringel: Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet 41, 161-70 (2004) (Pubitemid 38333792)
38. IG Maroulakou, W Oemler, SP Naber, I Klebba, C Kuperwasser, PN Tsichlis: Distinct roles of the three Akt isoforms in lactogenic differentiation and involution. J Cell Physiol 217, 468-77 (2008)
39. H Konishi, S Kuroda, M Tanaka, H Matsuzaki, Y Ono, K Kameyama, T Haga, U Kikkawa: Molecular cloning and characterization of a new member of the RAC protein kinase family: association of the pleckstrin homology domain of three types of RAC protein kinase with protein kinase C subspecies and beta gamma subunits of G proteins. Biochem Biophys Res Commun 216, 526-34 (1995)
40. MD Ringel, N Hayre, J Saito, B Saunier, F Schuppert, H Burch, V Bernet, KD Burman, LD Kohn, M Saji: Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 61, 6105-11 (2001) (Pubitemid 32762546)
41. TF Franke, DR Kaplan, LC Cantley, A Toker: Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 275, 665-8 (1997) (Pubitemid 27061333)
42. DR Alessi: Discovery of PDK1, one of the missing links in insulin signal transduction. Colworth Medal Lecture. Biochem Soc Trans 29, 1-14 (2001) (Pubitemid 32587470)
43. DD Sarbassov, DA Guertin, SM Ali, DM Sabatini: Phosphorylation and regulation of Akt/PKB by the rictormTOR complex. Science 307, 1098-101 (2005) (Pubitemid 40262113)
44. BD Manning, LC Cantley: AKT/PKB signaling: navigating downstream. Cell 29, 1261-74 (2007) (Pubitemid 46962095)
45. T Gao, F Furnari, AC Newton: PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 18, 13-24 (2005) (Pubitemid 40444644)
46. LC Trotman, A Alimonti, PP Scaglioni, JA Koutcher, C Cordon-Cardo, PP Pandolfi: Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441, 523-7 (2006) (Pubitemid 44050155)
47. JA Engelman, J Luo, LC Cantley: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7, 606-19 (2006) (Pubitemid 44100518)
48. H Lempiäinen, TD Halazonetis: Emerging common themes in regulation of PIKKs and PI3Ks. EMBO J 28, 3067-73 (2009)
49. R Williams, A Berndt, S Miller, WC Hon, X Zhang: Form and flexibility in phosphoinositide 3-kinases. Biochem Soc Trans 37, 615-26 (2009)
50. RJ Cain, AJ Ridley: Phosphoinositide 3-kinases in cell migration. Biol Cell 101, 13-29 (2009)
51. L Shayesteh, Y Lu, WL Kuo, R Baldocchi, T Godfrey, C Collins, D Pinkel, B Powell, GB Mills, JW Gray: PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21, 99-102 (1999) (Pubitemid 29036292)
52. PK Vogt, S Kang, MA Elsliger, M Gymnopoulos: Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem Sci 32, 342-9 (2007) (Pubitemid 47021415)
53. JP Gustin, B Karakas, MB Weiss, AM Abukhdeir, J Lauring, JP Garay, D Cosgrove, A Tamaki, H Konishi, Y Konishi, M Mohseni, G Wang, DM Rosen, SR Denmeade, MJ Higgins, MI Vitolo, KE Bachman, BH Park: Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci U S A 106, 2835-40 (2009)
54. KM Vasudevan, DA Barbie, MA Davies, R Rabinovsky, CJ McNear, JJ Kim, BT Hennessy, H Tseng, P Pochanard, SY Kim, IF Dunn, AC Schinzel, P Sandy, S Hoersch, Q Sheng, PB Gupta, JS Boehm, JH Reiling, S Silver, Y Lu, K Stemke-Hale, B Dutta, C Joy, AA Sahin, AM Gonzalez-Angulo, A Lluch, LE Rameh, T Jacks, DE Root, ES Lander, GB Mills, WC Hahn, WR Sellers, LA Garraway: AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16, 21-32 (2009)
55. DM Li, H Sun: TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 57, 2124-9 (1997) (Pubitemid 27247025)
56. J Li, C Yen, D Liaw, K Podsypanina, S Bose, SI Wang, J Puc, C Miliaresis, L Rodgers, R McCombie, SH Bigner, BC Giovanella, M Ittmann, B Tycko, H Hibshoosh, MH Wigler, R Parsons: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275,1943-7(1997) (Pubitemid 27148818)
57. PA Steck, MA Pershouse, SA Jasser, WK Yung, H Lin, AH Ligon, LA Langford, ML Baumgard, T Hattier, T Davis, C Frye, R Hu, B Swedlund, DH Teng, SV Tavtigian: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15, 356-62 (1997) (Pubitemid 27147102)
58. LC Cantley, BG Neel: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 96, 4240-5 (1999) (Pubitemid 29190320)
59. F Vazquez, WR Sellers: The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochim Biophys Acta 1470, M21-35 (2000)
60. T Maehama, JE Dixon: The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273, 13375-8 (1998) (Pubitemid 28268370)
61. V Stambolic, A Suzuki, JL de la Pompa, GM Brothers, C Mirtsos, T Sasaki, J Ruland, JM Penninger, DP Siderovski, TW Mak: Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95, 29-39 (1998) (Pubitemid 28458022)
62. H Sun, R Lesche, DM Li, J Liliental, H Zhang, J Gao, N Gavrilova, B Mueller, X Li, H Wu: PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A 96, 6199-204 (1999) (Pubitemid 29256643)
63. A Di Cristofano and PP Pandolfi: The multiple roles of PTEN in tumor suppression. Cell 100, 387-90 (2000)
64. JA Hobert, C Eng: PTEN hamartoma tumor syndrome: an overview. Genet Med 11, 687-94 (2009)
65. TD Bunney, M Katan: Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer 10, 342-52 (2010)
66. F Meng, R Henson, H Wehbe-Janek, K Ghoshal, ST Jacob, T Patel: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133, 647-58 (2007) (Pubitemid 47187346)
67. N Amodio, M Scrima, L Palaia, A Naeem Salman, A Quintiero, R Franco, G Botti, P Pirozzi, G Rocco, N De Rosa, G Viglietto: Oncogenic role of NEDD4-1, a PTENnegative regulator, in non small lung carcinomas (NSCLC). Am J Pathol. In press (2010)
68. A Di Cristofano, B Pesce, C Cordon-Cardo, PP Pandolfi: Pten is essential for embryonic development and tumour suppression. Nat Genet 19, 348-55 (1998) (Pubitemid 28357906)
69. K Podsypanina, LH Ellenson, A Nemes, J Gu, M Tamura, KM Yamada, C Cordon-Cardo, G Catoretti, PE Fisher, R Parsons: Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A 96, 1563-8 (1999) (Pubitemid 29098491)
70. A Suzuki, JL de la Pompa, V Stambolic, AJ Elia, T Sasaki, I del Barco Barrantes, A Ho, A Wakeham, A Itie, W Khoo, M Fukumoto, TW Mak: High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 8, 1169-78 (1998) (Pubitemid 28494715)
71. V Stambolic, MS Tsao, D Macpherson, A Suzuki, WB Chapman, TW Mak: High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/-mice. Cancer Res 60, 3605-11 (2000) (Pubitemid 30482183)
72. L Buday, J Downward: Many faces of Ras activation. Biochim Biophys Acta 1786, 178-87 (2008)
73. KA Miller, N Yeager, K Baker, XH Liao, S Refetoff, A Di Cristofano: Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Res 69, 3689-94 (2009)
74. SJ Cohen, L Ho, S Ranganathan, JL Abbruzzese, RK Alpaugh, M Beard, NL Lewis, S McLaughlin, A Rogatko, JJ Perez-Ruixo, AM Thistle, T Verhaeghe, H Wang, LM Weiner, JJ Wright, GR Hudes, NJ Meropol: Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol 21, 1301-6 (2003) (Pubitemid 46606407)
75. DW Ball, N Jin, DM Rosen, A Dackiw, D Sidransky, M Xing, BD Nelkin: Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab 92, 4712-8 (2007) (Pubitemid 350223448)
76. JE Dumont, F Lamy, P Roger, C Maenhaut: Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiol Rev 72, 667-697 (1992)
77. K Tanaka, Y Nagayama, T Nakano, N Takamura, H Namba, S Fukada, K Kuma, S Yamashita, M Niwa: Expression profile of receptor-type protein tyrosine kinase genes in the human thyroid. Endocrinology 139, 852-8 (1998) (Pubitemid 28510098)
78. MC Eggo, MC Sheppard: Autocrine growth factors produced in the thyroid. Mol Cell Endocrinol 100, 97-102 (1994) (Pubitemid 24109534)
79. BF Van der Laan, JL Freeman, SL Asa: Expression of growth factors and growth factor receptors in normal and tumorous human thyroid tissues. Thyroid 5, 67-73 (1995)
80. XP Pang, JM Hershman: Differential effects of growth factors on [3H] thymidine incorporation and [125I] iodine uptake in FRTL-5 rat thyroid cells. Proc Soc Exp Biol Med 194, 240-244 (1990) (Pubitemid 20214369)
81. T Kimura, JE Dumont, A Fusco, J Golstein: Insulin and TSH promote growth in size of PC Cl3 rat thyroid cells, possibly via a pathway different from DNA synthesis: comparison with FRTL-5 cells. Eur J Endocrinol 140, 94-103 (1999) (Pubitemid 29074774)
82. S Dremier, M Taton, K Coulonval, T Nakamura, K Matsumoto, JE Dumont: Mitogenic, dedifferentiating, and scattering effects of hepatocyte growth factor on dog thyroid cells. Endocrinology 135, 135-140 (1994) (Pubitemid 24203809)
83. M Santoro, F Carlomagno, ID Hay, MA Herrmann, M Grieco, R Melillo, MA Pierotti, I Bongarzone, G Della Porta, N Berger, JL Peix, C Paulin, N Fabien, G Vecchio, RB Jenkins, A Fusco: Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest 89, 1517-22 (1992)
84. YE Nikiforov, JM Rowland, KE Bove, H Monforte-Munoz, JA Fagin: Distinct pattern of ret oncogene rearrangements in morphological variants of radiationinduced and sporadic thyroid papillary carcinomas in children. Cancer Res 57, 1690-4 (1997) (Pubitemid 27199660)
85. CL Fenton, Y Lukes, D Nicholson, CA Dinauer, GL Francis, RM Tuttle: The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. J Clin Endocrinol Metab 85, 1170-5 (2000) (Pubitemid 32269367)
86. P Soares, E Fonseca, D Wynford-Thomas, M Sobrinho-Simões: Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms? J Pathol 18, 71-8 (1998) (Pubitemid 28266719)
87. MA Pierotti: Chromosomal rearrangements in thyroid carcinomas: a recombination or death dilemma. Cancer Lett 166, 1-7 (2001) (Pubitemid 32274279)
88. I Bongarzone, P Vigneri, L Mariani, P Collini, S Pilotti, MA Pierotti: RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clin Cancer Res 4, 223-8 (1998) (Pubitemid 28062900)
89. E Miyagi, M Braga-Basaria, E Hardy, V Vasko, KD Burman, S Jhiang, M Saji, MD Ringel: Chronic expression of RET/PTC 3 enhances basal and insulin-stimulated PI3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells. Mol Carcinog 41, 98-107 (2004) (Pubitemid 39336759)
90. R Mineo, A Costantino, F Frasca, L Sciacca, S Russo, R Vigneri, A Belfiore: Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels. Endocrinology 145, 4355-65 (2004) (Pubitemid 39120585)
91. P Bruni, A Boccia, G Baldassarre, F Trapasso, M Santoro, G Chiappetta, A Fusco, G Viglietto: PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1. Oncogene 19, 3146-55 (2000) (Pubitemid 30455926)
92. ML Motti, D Califano, G Troncone, C De Marco, I Migliaccio, E Palmieri, L Pezzullo, L Palombini, A Fusco, G Viglietto: Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization. Am J Pathol 166, 737-49 (2005) (Pubitemid 40315631)
93. G García-Rostán, AM Costa, I Pereira-Castro, G Salvatore, R Hernandez, MJ Hermsem, A Herrero, A Fusco, J Cameselle-Teijeiro, M Santoro: Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 65, 10199-207 (2005) (Pubitemid 41743711)
94. JC Ricarte-Filho, M Ryder, DA Chitale, M Rivera, A Heguy, M Ladanyi, M Janakiraman, D Solit, JA Knauf, RM Tuttle, RA Ghossein, JA Fagin: Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69, 4885-93 (2009)
95. M Miyakawa, T Tsushima, H Murakami, K Wakai, O Isozaki, K Takano: Increased expression of phosphorylated p70S6 kinase and Akt in papillary thyroid cancer tissues. Endocr J 50, 77-83 (2003) (Pubitemid 36305850)
96. J Abubaker, J Jehan, P Bavi, M Sultana, S Al-Harbi, M Ibrahim, A Al-Nuaim, M Ahmed, T Amin, M Al-Fehaily, O Al-Sanea, F Al-Dayel, S Uddin, KS Al-Kuraya: Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab 93, 611-8 (2008) (Pubitemid 351240838)
97. Z Liu, P Hou, M Ji, H Guan, K Studeman, K Jensen, V Vasko, AK El-Naggar, M Xing: Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 93, 3106-16 (2008)
98. JD Carpten, AL Faber, C Horn, GP Donoho, SL Briggs, CM Robbins, G Hostetter, S Boguslawski, TY Moses, S Savage, K Uhlik, A Lin, J Du, YW Qian, DJ Zeckner, G Tucker-Kellogg, J Touchman, K Patel, S Mousses, M Bittner, R Schevitz, MH Lai, KL Blanchard, JE Thomas: A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448, 439-44 (2007) (Pubitemid 47123510)
99. MA Davies, K Stemke-Hale, C Tellez, CL Calderone, W Deng, VG Prieto, AJ Lazar, JE Gershenwald, GB Mills: A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 99, 1265-8 (2008)
100. D Malanga, M Scrima, C De Marco, F Fabiani, N De Rosa, S De Gisi, N Malara, R Savino, G Rocco, G Chiappetta, R Franco, V Tirino, G Pirozzi, G Viglietto: Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 7, 665-9 (2008) (Pubitemid 351499006)
101. FE Bleeker, L Felicioni, F Buttitta, S Lamba, L Cardone, M Rodolfo, A Scarpa, S Leenstra, M Frattini, M Barbareschi, MD Grammastro, MG Sciarrotta, C Zanon, A Marchetti, A Bardelli: AKT1(E17K) in human solid tumours. Oncogene 27, 5648-50 (2008)
102. K Shoji, K Oda, S Nakagawa, S Hosokawa, G Nagae, Y Uehara, K Sone, Y Miyamoto, H Hiraike, O Hiraike-Wada, T Nei, K Kawana, H Kuramoto, H Aburatani, T Yano, Y Taketani: The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br J Cancer 101, 145-8 (2009)
103. JM Askham, F Platt, PA Chambers, H Snowden, CF Taylor, MA Knowles: AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can cooperate with E17K. Oncogene 29, 150-5 (2010)
104. J Lauring, DP Cosgrove, S Fontana, JP Gustin, H Konishi, AM Abukhdeir, JP Garay, Mohseni, GM Wang, MJ Higgins, D Gorkin, M Reis, B Vogelstein, K Polyak, Cowherd, PJ Buckhaults, BH Park: Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations. Oncogene 29, 2337-2345 (2010)
105. G Wu, E Mambo, Z Guo, S Hu, X Huang, SM Gollin, B Trink, PW Ladenson, D Sidransky, M Xing: Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab 90, 4688-93 (2005) (Pubitemid 41159359)
106. P Hou, D Liu, Y Shan, S Hu, K Studeman, S Condouris, Y Wang, A Trink, AK El-Naggar, G Tallini, V Vasko, M Xing: Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 13, 1161-1170 (2007) (Pubitemid 46424056)
107. Y Wang, P Hou, H Yu, W Wang, M Ji, S Zhao, S Yan, X Sun, D Liu, B Shi, G Zhu, S Condouris, M Xing: High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J Clin Endocrinol Metab 92, 2387-2390 (2007). (Pubitemid 46997152)
108. P Hou, M Ji, M Xing: Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer 113, 2440-7 (2008)
109. L Santarpia, AK El-Naggar, GJ Cote, JN Myers, SI Sherman: Phosphatidylinositol 3-kinase/akt and ras/rafmitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 93, 278-84 (2008)
110. AG Bader, S Kang, PK Vogt: Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A 103, 1475-9 (2006) (Pubitemid 43191190)
111. JA Engelman, L Chen, X Tan, K Crosby, AR Guimaraes, R Upadhyay, M Maira, K McNamara, SA Perera, Y Song, LR Chirieac, R Kaur, A Lightbown, J Simendinger, T Li, RF Padera, C García-Echeverría, R Weissleder, U Mahmood, LC Cantley, KK Wong: Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14, 1351-6 (2008)
112. S Liang, N Yang, Y Pan, S Deng, X Lin, X Yang, D Katsaros, KF Roby, TC Hamilton, DC Connolly, G Coukos, L Zhang: Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation. PLoS One 4, e4295 (2001)
113. CJ Guigon, L Zhao, MC Willingha, SY Cheng: PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer. Oncogene 28, 509-517 (2009)
114. Y Samuels, Z Wang, A Bardelli, N Silliman, J Ptak, S Szabo, Y Yan, A Gazdar, SM Powell, GJ Riggins, JK Willson, S Markowitz, KW Kinzler, B Vogelstein, VE Velculescu: High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004) (Pubitemid 38541907)
115. N Halachmi, S Halachmi, E Evron, P Cairns, K Okami, M Saji, WH Westra, MA Zeiger, J Jen,D Sidransky: Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors. Genes Chromosomes Cancer 23, 239-43 (1998) (Pubitemid 28465640)
116. PL Dahia, DJ Marsh, Z Zheng, J Zedenius, P Komminoth, T Frisk, G Wallin, R Parsons, M Longy, C Larsson, C Eng: Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 57, 4710-3 (1997) (Pubitemid 27468972)
117. JJ Yeh, DJ Marsh, J Zedenius, T Dwight, L Delbridge, BG Robinson, C Eng: Fine-structure deletion mapping of 10q22-24 identifies regions of loss of heterozygosity and suggests that sporadic follicular thyroid adenomas and follicular thyroid carcinomas develop along distinct neoplastic pathways. Genes Chromosomes Cancer 26, 322-8 (1999) (Pubitemid 29529577)
118. O Gimm, A Perren, LP Weng, DJ Marsh, JJ Yeh, U Ziebold, E Gil, R Hinze, L Delbridge, JA Lees, GL Mutter, BG Robinson, P Komminoth, H Dralle, C Eng: Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol 156, 1693-700 (2000) (Pubitemid 30646707)
119. LP Weng, WM Smith, JL Brown, C Eng: PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model. Hum Mol Genet 10, 605-16 (2001) (Pubitemid 32229365)
120. F Alvarez-Nuñez, E Bussaglia, D Mauricio, J Ybarra, M Vilar, E Lerma, A de Leiva, X Matias-Guiu; Thyroid Neoplasia Study Group: PTEN promoter methylation in sporadic thyroid carcinomas. Thyroid 16, 17-23 (2006) (Pubitemid 43346499)
121. U Schagdarsurengin, O Gimm, H Dralle, C Hoang-Vu, R Dammann: CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. Thyroid 16(7), 633-42 (2006)
122. V Vasko, M Ferrand, J Di Cristofaro, P Carayon, JF Henry, C de Micco: Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 88, 2745-52 (2003) (Pubitemid 36724451)
123. JM Shields, K Pruitt, A McFall, A Shaub, CJ Der: Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol 10, 147-54 (2000) (Pubitemid 30171309)
124. G Cheng, JL Meinkoth: Enhanced sensitivity to apoptosis in Ras-transformed thyroid cells. Oncogene 20, 7334-41 (2001) (Pubitemid 33078204)
125. V Gire and D Wynford-Thomas: RAS oncogene activation induces proliferation in normal human thyroid epithelial cells without loss of differentiation. Oncogene 9, 737-44 (2000) (Pubitemid 30107704)
126. V Gire, C Marshall, D Wynford-Thomas: PI-3-kinase is an essential anti-apoptotic effector in the proliferative response of primary human epithelial cells to mutant RAS. Oncogene 19, 2269-76 (2000) (Pubitemid 30307202)
127. RM Melillo, F Carlomagno, G De Vita, P Formisano, G Vecchio, A Fusco, M Billaud, M Santoro: The insulin receptor substrate (IRS)-1 recruits phosphatidylinositol 3-kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret. Oncogene 20, 209-18 (2001) (Pubitemid 32150266)
128. M Lodyga, V De Falco, XH Bai, A Kapus, RM Melillo, M Santoro, M Liu: XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway. Oncogene 28, 937-49 (2009)
129. V De Falco, V Guarino, L Malorni, AM Cirafici, F Troglio, M Erreni, G Pelicci, M Santoro, RM Melillo: RAI(ShcC/N-Shc)-dependent recruitment of GAB 1 to RET oncoproteins potentiates PI 3-K signalling in thyroid tumors. Oncogene 24, 6303-13 (2005) (Pubitemid 43080053)
130. DW Kim, JH Hwang, JM Suh, H Kim, JH Song, ES Hwang, IY Hwang, KC Park, HK Chung, JM Kim, J Park, BA Hemmings, M Shong: RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1. Mol Endocrinol 17, 1382-94 (2003) (Pubitemid 36819958)
131. HS Jung, DW Kim, YS Jo, HK Chung, JH Song, JS Park, KC Park, SH Park, JH Hwang, KW Jo, M. Shong: Regulation of protein kinase B tyrosine phosphorylation by thyroid-specific oncogenic RET/PTC kinases. Mol Endocrinol 19, 2748-59 (2005) (Pubitemid 41577247)
132. AK Siraj, P Bavi, J Abubaker, Z Jehan, M Sultana, F Al-Dayel, A Al-Nuaim, A Alzahrani, M Ahmed, O Al-Sanea, S Uddin, KS Al-Kuraya: Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy. J Pathol 213, 190-9 (2007) (Pubitemid 47612241)
133. MB Yaffe, K Rittinger, S Volinia, PR Caron, A Aitken, H Leffers, SJ Gamblin, SJ Smerdon, LCCantley: The structural basis for 14-3-3:phosphopeptide binding specificity. Cell 91, 961-71 (1997) (Pubitemid 28027829)
134. S Wullschleger, R Loewith, MN Hall: TOR signaling in growth and metabolism. Cell 124, 471-84 (2006) (Pubitemid 43199434)
135. D Ruggero, N Sonenberg: The Akt of translational control. Oncogene 24, 7426-34 (2005) (Pubitemid 41637982)
136. MA Bjornsti, PJ Houghton: Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell 5,519-23 (2004) (Pubitemid 38748913)
137. D Ruggero, PP Pandolfi: Does the ribosome translate cancer? Nat Rev Cancer 3, 179-92 (2003) (Pubitemid 37328870)
138. DR Plas, CB Thompson: Akt-dependent transformation: there is more to growth than just surviving. Oncogene 24, 7435-42 (2005) (Pubitemid 41637983)
139. H Seeliger, M Guba, A Kleespies, KW Jauch, CJ Bruns: Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev 26, 611-21 (2007) (Pubitemid 350115107)
140. A Astrinidis, EP Henske: Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene 24, 7475-81 (2005) (Pubitemid 41637987)
141. RT Abraham, JJ Gibbons: The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 13, 3109-14 (2007) (Pubitemid 46944891)
142. DA Guertin, DM Sabatini: Defining the role of mTOR in cancer. Cancer Cell 12, 9-22 (2007) (Pubitemid 47001784)
143. DD Sarbassov, SM Ali, S Sengupta, JH Sheen, PP Hsu, AF Bagley, AL Markhard, DM Sabatini: Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22, 159-68 (2006)
144. C Brewer, N Yeager, A Di Cristofano: Thyroidstimulating hormone initiated proliferative signals converge in vivo on the mTOR kinase without activating AKT. Cancer Res 67, 8002-6 (2007) (Pubitemid 47395133)
145. EW Arvisais, A Romanelli, X Hou, JS Davis: Tindependent phosphorylation of TSC2 and activation of mTOR and ribosomal protein S6 kinase signaling by prostaglandin F2{alpha}. J Biol Chem 281, 26904-13 (2006) (Pubitemid 44401719)
146. P Wlodarski, M Kasprzycka, X Liu, M Marzec, ES Robertson, A Slupianek, MA Wasik: Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signalregulated kinase kinase, insulin growth factor-I, and serum. Cancer Res 65, 7800-8 (2005) (Pubitemid 41297255)
147. LY Wing, HM Chen, PC Chuang, MH Wu, SJ Tsai: The mammalian target of rapamycin-p70 ribosomal S6 kinase but not phosphatidylinositol 3-kinase-Akt signaling is responsible for fibroblast growth factor-9-induced cell proliferation. J Biol Chem 280, 19937-47 (2005)
148. EC Souza, AS Figueiredo, WM Braga, BM Andrade, M Vaisman, LE Nasciutti, AC Ferreira, DP Carvalho: Mammaliam target of rapamycin (mTOR) down-regulates iodide uptake in thyrocytes. J Endocrinol 206, 113-20 (2010)
149. N Yeager, C Brewer, KQ Cai, XX Xu, A Di Cristofano: Mammalian target of rapamycin is the key effector of phosphatidylinositol-3-OH-initiated proliferative signals in the thyroid follicular epithelium. Cancer Res, 68(2), 444-9 (2008) (Pubitemid 351380070)
150. F Furuya, C Lu, MC Willingham, SY Cheng: Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. Carcinogenesis 28, 2451-8 (2007) (Pubitemid 350238946)
151. D Liu, P Hou, Z Liu, G Wu, M Xing: Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res 69, 7311-9 (2009)
152. N Jin, T Jiang, DM Rosen, BD Nelkin, DW Ball: Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab 94, 4107-4112 (2009)
153. C Papewalis, M Wuttke, S Schinner, HS Willenberg, AM Baran, WA Scherbaum, M Schott: Role of the novel mTOR inhibitor RAD001 (everolimus) in anaplastic thyroid cancer. Horm Metab Res 41, 752-6 (2009)
154. S Cory, DC Huang, JM Adams: The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22, 8590-8607 (2003) (Pubitemid 38028528)
155. NN Danial, SJ Korsmeyer: Cell death: critical control points. Cell 116, 205-219 (2004) (Pubitemid 38167313)
156. SR Datta, A Katsov, L Hu, A Petros, SW Fesik, MB Yaffe, ME Greenberg: 14-3-3 proteins and survival kinasescooperate to inactivate BAD by BH3 domain phosphorylation. Mol Cell 6, 41-51 (2000)
157. L del Peso, M González-García, C Page, R Herrera, G Nuñez: Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278, 687-9 (1997) (Pubitemid 27464966)
158. GJ Kops, BM Burgering: Forkhead transcription factors: new insights into protein kinase B (c-akt) signaling. J Mol Med 77, 656-65 (1999) (Pubitemid 29500958)
159. GJ Kops, ND de Ruiter, AM De Vries-Smits, DR Powell, JL Bos, BM Burgering: Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature 398, 630-4 (1999) (Pubitemid 29183692)
160. WH Biggs, J Meisenhelder, T Hunter, WK Cavenee, KC Arden: Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci U S A 96, 7421-6 (1999) (Pubitemid 29299677)
161. A Brunet, A Bonni, MJ Zigmond, MZ Lin, P Juo, LS Hu, MJ Anderson, KC Arden, J Blenis, ME Greenberg: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96, 857-68 (1999) (Pubitemid 29165088)
162. G Rena, S Guo, SC Cichy, TG Unterman, P Cohen: Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J Biol Chem 274, 17179-83 (1999)
163. H Tran, A Brunet, EC Griffith, ME Greenberg: The many forks in FOXO's road. Sci STKE 2003, RE5 (2003)
164. N Nakamura, S Ramaswamy, F Vazquez, S Signoretti, M Loda, WR Sellers: Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol 20, 8969-82 (2000) (Pubitemid 32245927)
165. RH Medema, GJ Kops, JL Bos, BM Burgering: AFXlike Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404, 782-7 (2000) (Pubitemid 30212408)
166. PF Dijkers, RH Medema, JW Lammers, L Koenderman, PJ Coffer: Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 10, 1201-1204 (2000)
167. G De Vita, MT Berlingieri, R Visconti, MD Castellone, G Viglietto, G Baldassarre, M Zannini, A Bellacosa, PN Tsichlis, A Fusco, M Santoro: Akt/protein kinase B promotes survival and hormone-independent proliferation of thyroid cells in the absence of dedifferentiating and transforming effects. Cancer Res 60, 3916-20 (2000) (Pubitemid 32204587)
168. LD Mayo, DB Donner: A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A 98, 11598-603 (2001) (Pubitemid 32928774)
169. BP Zhou, Y Liao, W Xia, Y Zou, B Spohn, MC Hung: HER-2/neu induces p53 ubiquitination via Aktmediated MDM2 phosphorylation. Nat Cell Biol 4, 736 (2001)
170. A Villunger, EM Michalak, L Coultas, F Müllauer, G Böck, MJ Ausserlechner, JM Adams, A Strasser: p53-and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302, 1036-8 (2003) (Pubitemid 37386194)
171. LP Kane, VS Shapiro, D Stokoe, A Weiss: Induction of NF-kappaB by the Akt/PKB kinase. Curr Biol 9, 601-4 (1999)
172. A Khwaja: Akt is more than just a Bad kinase. Nature 401, 33-4 (1999)
173. ON Ozes, LD Mayo, JA Gustin, SR Pfeffer, LM Pfeffer, DB Donner: NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401, 82-5 (1999)
174. JA Romashkova, SS Makarov: NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401, 86-90 (1999)
175. S Ghosh, MJ May, EB Kopp: NF-kB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16, 225-60 (1998) (Pubitemid 28183365)
176. E Zandi, M Karin: Bridging the gap: composition, regulation, and physiological function of the IkB kinase complex. Mol Cell Biol 19, 4547-51 (1999) (Pubitemid 29289492)
177. M Karin, M Delhase: The IkB kinase (IKK) and NFkB: key elements of proinflammatory signalling. Semin Immunol 12, 85-98 (2000) (Pubitemid 30114019)
178. CY Wang, MW Mayo, RG Korneluk, DV Goeddel, AS Baldwin: NF-kB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281, 1680-3 (1998)
179. MX Wu, Z Ao, KV Prasad, R Wu, SF Schlossman: IEX-1L, an apoptosis inhibitor involved in NF-kBmediated cell survival. Science 281, 998-1001 (1998) (Pubitemid 28399251)
180. RC Bargou, F Emmerich, D Krappmann, K Bommert, MY Mapara, W Arnold, HD Royer, E Grinstein, A Greiner, C Scheidereit, B Dorken: Constitutive nuclear factor-kBRelA activation is required for proliferation and survival of Hodgkins disease tumor cells. J Clin Invest 100, 2961-9 (1997) (Pubitemid 28022832)
181. DC Duffey, Z Chen, G Dong, FG Ondrey, JS Wolf, K Brown, U Siebenlist, C van Waes: Expression of a dominant-negative mutant inhibitor-kBa of nuclear factorkB in human head and neck squamous cell carcinomainhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 59, 3468-74 (1999) (Pubitemid 29334510)
182. S Huang, CA Pettaway, H Uehara, CD Bucana and IJ Fidler: Blockade of NF-kB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20, 4188-97 (2001) (Pubitemid 32762193)
183. JA Romashkova, SS Makarov: NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401, 86-90 (1999)
184. D Bai, L Ueno, PK Vogt: Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt. Int J Cancer 125, 2863-70 (2009)
185. S Vasudevan, N Garneau, D Tu Khounh, SW Peltz: p38 mitogen-activated protein kinase/Hog1p regulates translation of the AU-rich-element-bearing MFA2 transcript. Mol Cell Biol 25, 9753-63 (2005) (Pubitemid 41572726)
186. CY Wang, WB Zhong, TC Chang, SM Lai, YF Tsai: Tumor necrosis factor alpha induces three-dimensional cytomorphologic differentiation of human anaplastic thyroid carcinoma cells through activation of nuclear factor kappaB. Cancer 95, 1827-33 (2002)
187. I Palona, H Namba, N Mitsutake, D Starenki, A Podtcheko, I Sedliarou, A Ohtsuru, V Saenko, Y Nagayama, K Umezawa, S Yamashita: BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kB activation. Endocrinology 147, 5699-707 (2006) (Pubitemid 44833486)
188. H Namba, V Saenko, S Yamashita: Nuclear factor-kB in thyroid carcinogenesis and progression: a novel therapeutic target for advanced thyroid cancer. Arq Bras Endocrinol Metab 51, 843-851 (2007)
189. R Visconti, J Cerutti, S Battista, M Fedele, F Trapasso, K Zeki, MP Miano, F de Nigris, L Casalino, F Curcio, M Santoro, A Fusco: Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkB p65 protein expression. Oncogene 15, 1987-94 (1997)
190. D Starenki, H Namba, V Saenko, A Ohtsuru, S Yamashita: Inhibition of nuclear factor-kB cascade potentiates the effect of a combination treatment of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 89, 410-8 (2004) (Pubitemid 38183911)
191. F Pacifico, C Mauro, C Barone, E Crescenzi, S Mellone, M Monaco, G Chiappetta, G Terrazzano, D Liguoro, P Vito, E Consiglio, S Formisano, A Leonardi: Oncogenic and anti-apoptotic activity of NF-kB in human thyroid carcinomas. J Biol Chem 279, 54610-9 (2004) (Pubitemid 40053204)
192. CS Mitsiades, V Kotoula, V Poulaki, E Sozopoulos, J Negri, E Charalambous, G Fanourakis, G Voutsinas, S Tseleni-Balafouta, N Mitsiades: Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. J Clin Endocrinol Metab 91, 3662-6 (2006) (Pubitemid 44402152)
193. T Bauerle, RE Schweppe, BR Haugen: Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion. Mol Cancer 9, 117 (2010)
194. M Festa, A Petrella, S Alfano, L Parente: Rroscovitine sensitizes anaplastic thyroid carcinoma cells to TRAIL-induced apoptosis via regulation of IKK/NFkappaB pathway. Int J Cancer 124, 2728-36 (2009)
195. Z Meng, N Mitsutake, M Nakashima, D Starenki, M Matsuse, S Takakura, H Namba, V Saenko, K Umezawa, A Ohtsuru, S Yamashita: Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells. Endocrinology 149, 5357-65 (2008)
196. W Zhu, Y Ou, Y Li, R Xiao, M Shu, Y Zhou, J Xie, S He, P Qiu, G Yan. A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factorkappa B pathway. Mol Pharmacol 75, 812-9 (2009)
197. J Saito, AD Kohn, RA Roth, Y Noguchi, I Tatsumo, A Hirai, K Suzuki, LD Kohn, M Saji, MD Ringel: Regulation of FRTL-5 thyroid cell growth by phosphatidylinositol (OH) 3 kinase-dependent Aktmediated signaling. Thyroid 11, 339-351 (2001) (Pubitemid 32422626)
198. LP Weng, O Gimm, JB Kum, WM Smith, XP Zhou, D Wynford-Thomas, G Leone, C Eng: Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death. Hum Mol Genet, 10(3), 251-8 (2001) (Pubitemid 32123984)
199. J Liang, J Zubovitz, T Petrocelli, R Kotchetkov, MK Connor, K Han, JH Lee, S Ciarallo, S Catzavelos, R Beniston, E Franssen, JM Slingerland: PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 8, 1153-60 (2002) (Pubitemid 35175971)
200. G Viglietto, ML Motti, P Bruni, RM Melillo, A D'Alessio, D Califano, F Vinci, G Chiappetta, P Tsichlis, A Bellacosa, A Fusco, M Santoro: Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 8, 1136-44 (2002) (Pubitemid 35175969)
201. N Fujita, S Sato, K Katayama, T Tsuruo: Aktdependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J Biol Chem 277, 28706-13 (2002)
202. ML Motti, C De Marco, D Califano, A Fusco, G Viglietto: Akt-dependent T198 phosphorylation ofcyclin-dependent kinase inhibitor p27kip1 in breast cancer. Cell Cycle 3, 1074-80 (2004) (Pubitemid 40268668)
203. I Shin, J Rotty, FY Wu, CL Arteaga: Phosphorylation of p27Kip1 at Thr-157 interferes with its association with importin alpha during G1 and prevents nuclear re-entry. J Biol Chem 280, 6055-63 (2005) (Pubitemid 40280089)
204. T Sekimoto, M Fukumoto, Y Yoneda: 14-3-3 suppresses the nuclear localization of threonine 157-phosphorylated p27(Kip1). EMBO J 23, 1934-42 (2004) (Pubitemid 38902071)
205. G Viglietto, ML Motti, A Fusco: Understanding p27(kip1) deregulation in cancer: down-regulation or mislocalization. Cell Cycle 1, 394-400 (2002)
206. A Besson, HC Hwang, S Cicero, SL Donovan, M Gurian-West, D Johnson, BE Clurman, MA Dyer, JM Roberts: Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev 21, 1731-46 (2007) (Pubitemid 47076473)
207. A Besson, M Gurian-West, A Schmidt, A Hall, JM Roberts: p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev 18, 862-76 (2004) (Pubitemid 38529656)
208. S Karger, C Weidinger, K Krause, SY Sheu, T Aigner, O Gimm, KW Schmid, H Dralle, D Fuhrer: FOXO3a: a novel player in thyroid carcinogenesis? Endocr Relat Cancer 16, 189-99 (2009)
209. G Chiappetta, C De Marco, A Quintiero, D Califano, S Gherardi, D Malanga, M Scrima, C Montero-Conde, L Cito, M Monaco, ML Motti, R Pasquinelli, V Agosti, M Robledo, A Fusco, G Viglietto: Overexpression of the Sphase kinase-associated protein 2 in thyroid cancer. Endocr Relat Cancer 14, 405-20 (2007) (Pubitemid 47242639)
210. ML Motti, C De Marco, D Califano, S De Gisi, D Malanga, G Troncone, A Persico, S Losito, F Fabiani, M Santoro, G Chiappetta, A Fusco, G Viglietto: Loss of p27 expression through RAS->BRAF->MAP kinase-dependent pathway in human thyroid carcinomas. Cell Cycle 6, 2817-25 (2007) (Pubitemid 350277175)
211. D Vitagliano, F Carlomagno, ML Motti, G Viglietto, YE Nikiforov, MN Nikiforova, JM Hershman, AJ Ryan, A Fusco, RM Melillo, M Santoro: Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells. Cancer Res 64, 3823-9 (2004) (Pubitemid 38697291)
212. M Fedele, D Palmieri, G Chiappetta, R Pasquinelli, I De Martino, C Arra, G Palma, T Valentino, GM Pierantoni, G Viglietto, JL Rothstein, M Santoro, A Fusco: Impairment of the p27kip1 function enhances thyroid carcinogenesis in TRK-T1 transgenic mice. Endocr Relat Cancer 16, 483-90 (2009)
213. DA Cross, DR Alessi, P Cohen, M Andjelkovich, BA Hemmings: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785-9 (1995) (Pubitemid 26004411)
214. JA Diehl, M Cheng, MF Roussel, CJ Sherr: Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12, 3499-511 (1998) (Pubitemid 28553242)
215. M Welcker, J Singer, KR Loeb, J Grim, A Bloecher, M Gurien-West, BE Clurman, JM Roberts: Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol Cell 12, 381-92 (2003) (Pubitemid 37238925)
216. ES Kandel, J Skeen, N Majewski, A Di Cristofano, PP Pandolfi, CS Feliciano, A Gartel, N Hay: Activation of Akt/protein kinase B overcomes a G(2)/M cell cycle checkpoint induced by DNA damage. Mol Cell Biol 22, 7831-41 (2002) (Pubitemid 35217294)
217. E Shtivelman, J Sussman, D Stokoe: A role for PI 3-kinase and PKB activity in the G2/M phase of the cell cycle. Curr Biol 12, 919-24 (2002) (Pubitemid 34689227)
218. FW King, J Skeen, N Hay, E Shtivelman: Inhibition of Chk1 by activated PKB/Akt. Cell Cycle 3, 34-7 (2004)
219. J Puc, M Keniry, HS Li, TK Pandita, AD Choudhury, L Memeo, M Mansukhani, VV Murty, Z Gaciong, SE Meek, H Piwnica-Worms, H Hibshoosh, R. Parsons: Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 7, 193-204 (2005) (Pubitemid 40248344)
220. A Abulaiti, AJ Fikaris, OM Tsygankova, JL. Meinkoth: Ras induces chromosome instability and abrogation of the DNA damage response. Cancer Res 66, 10505-12 (2006) (Pubitemid 44799772)
221. AD Laird, JM Cherrington: Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin Investig Drugs 12, 51-64 (2003) (Pubitemid 36104643)
222. SI Sherman. Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab, 713-722 (2009)
223. SI Sherman: Targeted therapy of thyroid cancer. Biochem Pharmacol 80, 592-601 (2010)
224. C Garcia-Echeverria, WR Sellers: Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27, 5511-5526 (2008)
225. SI Sherman, LJ Wirth, JP Droz, M Hofmann, L Bastholt, RG Martins, L Licitra, MJ Eschenberg, YN Sun, T Juan, DE Stepan and MJ Schlumberger: Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359, 31-42 (2008) (Pubitemid 351931094)
226. EE Cohen, LS Rosen, EE Vokes, MS Kies, AA Forastiere, FP Worden, MA Kane, E Sherman, S Kim, PBycott, M Tortorici, DR Shalinsky, KF Liau, RB Cohen: Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26, 4708-4713 (2008)
227. CW Lindsley: The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation: a 2009 update. Curr Top Med Chem 10, 458-77 (2010)
228. Q Li, GD Zhu: Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer. Curr Top Med Chem 2, 939-971 (2002)
229. M Gassel, CB Breitenlechner, P Ruger, U Jucknischke, T Schneider, R Huber, D Bossemeyer, RA Engh: Mutants of protein kinase A that mimic the ATPbinding site of protein kinase B (Akt). J Mol Biol 329, 1021-1034 (2003) (Pubitemid 36683158)
230. CB Breitenlechner, WG Friebe, E Brunet, G Werner, K Graul, U Thomas, KP Kunkele, W Schafer, M Gassel, D Bossemeyer, R Huber, RA Engh, B Masjost: Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants. J Med Chem 48, 163-170 (2005) (Pubitemid 40105257)
231. CB Breitenlechner, T Wegge, L Berillon, K Graul, K Marzenell, WG Friebe, U Thomas, R Schumacher, R Huber, RA Engh, B. Masjost: Structure-based optimization of novel azepane derivatives as PKB inhibitors. J Med Chem 47, 1375-1390 (2004) (Pubitemid 38327465)
232. Y Luo, AR Shoemaker, X Liu, KW Woods, SA Thomas, R de Jong, EK Han, T Li, VS Stoll, JA Powlas, A Oleksijew, MJ Mitten, Y Shi, R Guan, TP McGonigal, V Klinghofer, EF Johnson, JD Leverson, JJ Bouska, M Mamo, RA Smith, EE Gramling-Evans, BA Zinker, AK Mika, PT Nguyen, T Oltersdorf, SH Rosenberg, Q Li, VL Giranda: Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Res 4, 977-986 (2005) (Pubitemid 40909080)
233. Y Shi, X Liu, E Han, R Guan, AR Shoemaker, A Oleksijew, KW Woods, JP Fisher, V Klinghofer, L Lasko, T McGonigal, Q Li, SH Rosenberg, VL Giranda, Y Luo: Optimal classes of chemotherapeutic agents sensitized by specific small-molecule inhibitors of akt in vitro and in vivo. Neoplasia 7, 992-1000 (2005)
234. N Rhodes, DA Heerding, DR Duckett, DJ Eberwein, VB Knick, TJ Lansing, RT McConnell, TM Gilmer, SY Zhang, K Robell, JA Kahana, RS Geske, EV Kleymenova, AE Choudhry, Z Lai, JD Leber, EA Minthorn, SL Strum, ER Wood, PS Huang, RA Copeland, R Kumar: Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res 68, 2366-2374 (2008) (Pubitemid 351521811)
235. BT Hennessy, Y Lu, E Poradosu, Q Yu, S Yu, H Hall, MS Carey, M Ravoori, AM Gonzalez-Angulo, R Birch, IC Henderson, V Kundra, GB Mills: Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res 13, 7421-31 (2007)
236. J LoPiccolo, GM Blumenthal, WB Bernstein, PA Dennis: Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 11, 32-50 (2008)
237. MP Wymann, G Bulgarelli-Leva, MJ Zvelebil, L Pirola, B Vanhaesebroeck, MD Waterfield, G Panayotou: Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol 16, 1722-1733 (1996) (Pubitemid 26095645)
238. CJ Vlahos, WF Matter, KY Hui, RF Brown: A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269, 5241-5248 (1994)
239. K Yu, J Lucas, T Zhu, A Zask, C Gaydos, L Toral-Barza, J Gu, F Li, I Chaudhary, P Cai, J Lotvin, R Petersen, M Ruppen, M Fawzi, S Ayral-Kaloustian, J Skotnicki, T Mansour, P Frost, J Gibbons: PWT-458, a novel pegylated-17- dydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors. Cancer Biol Ther 4, 538-545 (2005) (Pubitemid 41351227)
240. NT Ihle, G Paine-Murrieta, MI Berggren, A Baker, WRTate, P Wipf, RT Abraham, DL Kirkpatrick, G Powis: The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther 4, 1349-1357 (2005)
241. AL Howes, GG Chiang, ES Lang, CB Ho, G Powis, K Vuori, RT Abraham: The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol Cancer Ther 6, 2505-2514 (2007) (Pubitemid 47480416)
242. S Jia, TM Roberts, JJ Zhao: Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol 21, 199-208 (2009)
243. NT Ihle, R Lemos, P Wipf, A Yacoub, C Mitchell, D Siwak, GB Mills, P Dent, DL Kirkpatrick, G Powis: Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 69, 143-50 (2009)
244. V Serra, B Markman, M Scaltriti, PJ Eichhorn, V Valero, M Guzman, ML Botero, E Llonch, F Atzori, S Di Cosimo, M Maira, C Garcia-Echeverria, JL Parra, J Arribas, J Baselga: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68, 8022-30 (2008)
245. S Sato, N Fujita, T Tsuruo: Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 21, 1727-1738 (2002) (Pubitemid 34259036)
246. D Komander, GS Kular, J Bain, M Elliott, DR Alessi, DM Van Aalten: Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition. Biochem J 375, 255-262 (2003) (Pubitemid 37315433)
247. S Welch, HW Hirte, MS Carey, SJ Hotte, MS Tsao, S Brown, GR Pond, JE Dancey, AM Oza: UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium. Gynecol Oncol 106, 305-310 (2007) (Pubitemid 47096653)
248. RI Feldman, JM Wu, MA Polokoff, MJ Kochanny, H Dinter, D Zhu, SL Biroc, B Alicke, J Bryant, S Yuan, BO Buckman, D Lentz, M Ferrer, M Whitlow, M Adler, S Finster, Z Chang, DO Arnaiz: Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem 280, 19867-19874 (2005) (Pubitemid 41379514)
249. I Islam, G Brown, J Bryant, P Hrvatin, MJ Kochanny, GB Phillips, S Yuan, M Adler, M Whitlow, D Lentz, MA Polokoff, J Wu, J Shen, J Walters, E Ho, B Subramanyam, D Zhu, RI Feldman, DO Arnaiz: Indolinone based phosphoinositide- dependent kinase-1 (PDK1) inhibitors. Part 2: optimization of BX-517. Bioorg Med Chem Lett 17, 3819-3825 (2007) (Pubitemid 46920958)
250. I Islam, J Bryant, YL Chou, MJ Kochanny, W Lee, GB Phillips, H Yu, M Adler, M Whitlow, E Ho, D Lentz, MA Polokoff, B Subramanyam, JM Wu, D Zhu, RI Feldman, DO Arnaiz: Indolinone based phosphoinositidedependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. Bioorg Med Chem Lett 17, 3814-3818 (2007) (Pubitemid 46920915)
251. S Arico, S Pattingre, C Bauvy, P Gane, A Barbat, P Codogno, E Ogier-Denis: Celecoxib induces apoptosis by inhibiting 3-phosphoinositide- dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 277, 27613-27621 (2002) (Pubitemid 34966703)
252. A Fasolo, C Sessa: mTOR inhibitors in the treatment of cancer. Expert Opin Investig Drugs 17, 1717-34 (2008)
253. JA Engelman, L Chen, X Tan, K Crosby, AR Guimaraes, R Upadhyay, M Maira, K McNamara, SA Perera, Y Song, LR Chirieac, R Kaur, A Lightbown, J Simendinger, T Li, RF Padera, C García-Echeverría, R Weissleder, U Mahmood, LC Cantley, KK Wong. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14, 1351-6 (2008)
254. KP Hoeflich, C O'Brien, Z Boyd, G Cavet, S Guerrero, K Jung, T Januario, H Savage, E Punnoose, T Truong, W Zhou, L Berry, L Murray, L Amler, M Belvin, LS Friedman, MR Lackner: In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basallike breast cancer models. Clin Cancer Res 15, 4649-64 (2009)
255. N Yeager, A Klein-Szanto, S Kimura, A Di Cristofano: Pten loss in the mouse thyroid causes goiter and follicular adenomas: insights into thyroid function and Cowden disease pathogenesis. Cancer Res 67, 959-66 (2007)